Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Manag care"'
Autor:
Ervant J Maksabedian Hernandez, Mahdi Gharaibeh, Donna McMorrow, Machaon Bonafede, Bradley S. Stolshek
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1039-1049
Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic and nonbiologic medications with different mechanisms of action. Data describing disease activity levels in RA are not di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72af61a590e43fef776814d34cf48c0c
https://doi.org/10.18553/jmcp.2020.26.8.1039
https://doi.org/10.18553/jmcp.2020.26.8.1039
Autor:
Oluwaseyi Dina, Jeffrey Trocio, Anagha Nadkarni, Alpesh Amin, Onur Baser, Lien Vo, Jack Mardekian, Lisa Rosenblatt, Qisu Zhang, Hannah Le, Allison Keshishian, Xianchen Liu
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:639-651
Clinical trials have shown that direct oral anticoagulants (DOACs)-including dabigatran, rivaroxaban, apixaban, and edoxaban-are at least as effective and safe as warfarin for the risk of stroke/systemic embolism (SE) and major bleeding (MB) in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0774e0d81b39d7b6cb4d0ec62cb9b8
https://doi.org/10.18553/jmcp.2020.26.5.639
https://doi.org/10.18553/jmcp.2020.26.5.639
Autor:
R. Brett McQueen, Daniel A. Ollendorf, Richard H. Chapman, Melanie D Whittington, Jonathan D. Campbell, Foluso Agboola, Patricia G Synnott, Varun M. Kumar
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:80-87
Rheumatoid arthritis is associated with a societal burden greater than $39 billion annually. Novel treatments, known as targeted immune modulators (TIMs), are expensive but effective, producing improvements in response rates compared with conventiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd653356328e2de958bf5a07e83ed059
https://doi.org/10.18553/jmcp.2019.25.1.080
https://doi.org/10.18553/jmcp.2019.25.1.080
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:1306-1308
This article has been corrected. Please see J Manag Care Spec Pharm, 2020;26(3):336 DISCLOSURES: No funding supported the writing of this commentary. The authors are employed by Prime Therapeutics,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19b9db7d87bf9cfc9250e4a1025809bd
https://doi.org/10.18553/jmcp.2019.25.12.1306
https://doi.org/10.18553/jmcp.2019.25.12.1306
Autor:
Gema Robledo, Raquel Ríos Fernández, Antonio Alvarez de Cienfuegos, Miguel A. González-Gay, José Alberto García-Gómez, Lucia Cantero-Nieto, Javier Ibáñez, Norberto Ortego
Publikováno v:
Abstracts Accepted for Publication.
Background Rheumatoid Arthritis (RA) is one of the chronic autoimmune diseases with an estimated prevalence of 1 to 2 percent of the total population in the world. RA patients have an increased risk of morbidity and mortality from cardiovascular (CV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5bc9a0a3b1c9477d32c3e16d811a428
https://doi.org/10.1136/annrheumdis-2019-eular.7766
https://doi.org/10.1136/annrheumdis-2019-eular.7766
Publikováno v:
Abstracts Accepted for Publication.
Background: Adherence to therapy in chronic diseases such as inflammatory rheumatic diseases (CIRD), inflammatory bowel diseases (IBD) and psoriasis (Pso) is a major condition to achieve positive outcomes. Patient support programs (PSPs) were develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5439bc2c9ee8410127e095787be4033b
https://doi.org/10.1136/annrheumdis-2019-eular.6018
https://doi.org/10.1136/annrheumdis-2019-eular.6018
Publikováno v:
Abstracts Accepted for Publication.
Background: Adalimumab patient support programmes (A-PSPs) are offered to patients with chronic inflammatory indications creating the need to study how such A-PSPs assist patients and other stakeholders in improving health outcomes. A deeper understa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88da2bcdc9fd8cdbd65ed8364b5eb864
https://doi.org/10.1136/annrheumdis-2019-eular.6258
https://doi.org/10.1136/annrheumdis-2019-eular.6258
Autor:
Paloma Vela-Casasempere, Antonio Palazon Bru, Rocio Caño-Alameda, Marta Elvira, Silvia Gomez-Sabater
Publikováno v:
Abstracts Accepted for Publication.
Background Osteoporotic hip fractures have a profound impact on the physical health and psychosocial wellbeing of patients, with considerable economic implications. More than 20% of individuals experience a subsequent hip fracture in the following ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::210af8ae15eb0720a557b2de56acabb6
https://doi.org/10.1136/annrheumdis-2019-eular.3633
https://doi.org/10.1136/annrheumdis-2019-eular.3633
Publikováno v:
Abstracts Accepted for Publication.
Background Despite the advancements in management of rheumatoid arthritis (RA) in the last two decades, there are still a significant number of patients who cannot achieve low disease states or remission with the current available therapy. Granulocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94c9b7ee80d0df8d6f7c57fce76c7285
https://doi.org/10.1136/annrheumdis-2019-eular.3470
https://doi.org/10.1136/annrheumdis-2019-eular.3470
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Chronic hepatitis C treatment has changed with the direct-acting antivirals (DAAs) for the hepatitis C virus (HCV) with high levels of safety and effectiveness. Available data from clinical trials reveal that baseline factors at the beginn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::375460cab68c8f5b0e5751b5c935c986
https://doi.org/10.1136/ejhpharm-2019-eahpconf.433
https://doi.org/10.1136/ejhpharm-2019-eahpconf.433